⏰ #StartingShortly! $ERNA is about to begin its #VirtualInvestor Closing Bell segment. Tune in for the latest company updates and take part in the live Q&A. Join here: bit.ly/4B4yXcD #CellTherapy #Oncology #Hope #DeliveringHope

🔔Happening Today at 4 PM ET! Don't miss $ERNA live during its #VirtualInvestor Closing Bell segment for the latest corporate updates, recent progress highlights, and a look at upcoming priorities. Watch live here: bit.ly/4B4yXcD #CellTherapy #Hope #DeliveringHope

Tune In Tomorrow at 4 PM ET Hear from Ernexa Therapeutics CEO Sanjeev Luther during a live #VirtualInvestor Closing Bell segment as he discusses recent developments and what's ahead for $ERNA. Don't miss it: bit.ly/4B4yXcD #CellTherapy #Oncology #Hope #DeliveringHope

📅 Save The Date! $ERNA will take part in a #VirtualInvestor Closing Bell segment on Thursday, October 15 at 4 PM ET. Tune in to hear key updates from CEO Sanjeev Luther. Register Here: bit.ly/4B4yXcD #CellTherapy #Oncology #Hope #DeliveringHope

Hear from $OTLK CFO Kevin Lundquist in the latest Virtual Investor "What This Means" segment as he discusses joining Outlook Therapeutics following FDA approval and the Company’s path forward toward U.S. commercialization. Watch here: vimeo.com/1233136691/392a8c0… #Ophthalmology

$OTLK CEO Bob Jahr joins Virtual Investor’s “CEO Connect” to discuss the FDA approval and its plans for its U.S. commercial launch and the opportunity ahead in the wet AMD market. Watch here: vimeo.com/1225420337/fcc14a4… @OutlookTx #WetAMD

$CNSP Chief Business Officer, Dylan Wenke, joins Virtual Investor’s “What This Means” series to discuss the Company’s business development strategy as it builds an oncology or neurology pipeline with best-in-class potential. 🔗 vimeo.com/1222840808/9bb3667… @cns_pharma

Virtual Investor Launches "Why Now" On-Demand Conference Featuring Public Company CEOs Nine CEOs. Nine investment stories. 60 seconds each to answer the question that matters most to investors: Why now? Access the Conference Here: virtualinvestorco.com/why-no… $AIM $AKTX $CNSP $DARE $NVNO $ERNA $GRI $MBRX $OTLK @AimImmuno @AkariTX @cns_pharma @DareBioscience @enVVenoMedical @ErnexaTx @GRI_BIO @moleculinbio @OutlookTx

Restoring vision means restoring possibility. Hear CEO Bob Jahr discuss why this is an exciting time for Outlook Therapeutics and its mission to expand retinal treatment options. Watch the Virtual Investor Why Now Series: vimeo.com/1221551545/7e3fa72… @OutlookTx #ClinicalInsights #RetinaResearch #DataUpdates #EyeHealth $OTLK #VirtualInvestor

Some of the biggest challenges in cancer require bold thinking. CEO Walter Klemp explains why Moleculin is focused on developing new therapies for patients with limited treatment options. Watch the Virtual Investor Why Now Series: vimeo.com/1221551891/6004be1… @MoleculinBio $MBRX #AML #AcuteMyeloidLeukemia #CancerResearch #VirtualInvestor

New discoveries have the power to change lives. CEO Marc Hertz shares why targeting NKT cell biology could open new possibilities for patients with inflammatory and fibrotic diseases. Watch the Virtual Investor Why Now Series: vimeo.com/1221551816/88996c0… @GRIBio #IPF #IdiopathicPulmonaryFibrosis #VirtualInvestor $GRI

Innovation can begin with improving everyday life. CEO Robert Berman shares why bringing new treatment options to patients with severe deep venous insufficiency remains the company's focus. Watch the Virtual Investor Why Now Series: vimeo.com/1221551928 @enVVenoMed $NVNO #VenousDisease #CVD #CVI #VenousCare #VirtualInvestor

Hope starts with pursuing what's possible. CNS Pharmaceuticals Participates in the Virtual Investor “Why Now” On-Demand Conference Watch the Virtual Investor Why Now Series: vimeo.com/1221551759/6f89b28… @cns_pharma $CNSP #VirtualInvestor

DARE CEO Sabrina Martucci Johnson shares why innovation in women’s health could help address longstanding gaps in care and create new possibilities for patients. Watch the Virtual Investor Why Now Series: vimeo.com/1221551789/07e0078… @DareBioscience #WomensHealth #Biotech #VaginalHealth #PatientCare #VirtualInvestor

Big ideas often begin with a simple question: What if we could do better? CEO Sanjeev Luther discusses Ernexa's vision for advancing cell therapy and the future of cancer treatment. Watch the Virtual Investor Why Now Series: vimeo.com/1221551802/62bd8a4… @ErnexaTx $ERNA #OvarianCancer #CancerResearch #DeliveringHope #VirtualInvestor

The next generation of cancer therapies starts with innovation. CEO Abizer Gaslightwala shares why Akari's novel ADC platform is designed to help shape what's next in oncology. Watch the Virtual Investor Why Now Series: vimeo.com/1221551737/264a500… @AkariTx $AKTX #Oncology #ADCS #AntibodyDrugConjugates #VirtualInvestor

Every breakthrough begins with a reason to keep pushing forward. Hear CEO Thomas Equels explain why advancing new approaches for pancreatic cancer patients matters now in the Virtual Investor Why Now Series. Watch here: vimeo.com/1221551700/2b9974a… @AIMimmuno $AIM #PancreaticCancer #Oncology #CancerResearch #VirtualInvestor @InvestorVirtual

$DARE participates in a Virtual Investor “CEO Connect” segment highlighting the Company’s commercial transformation and pipeline momentum. CEO Sabrina Martucci Johnson discusses Ovaprene’s positive interim Phase 3 results and what’s ahead for Daré. 🔗: vimeo.com/1221118714/7bdfdec…